[Form 4] Life360, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Life360 director John Philip Coghlan reported sales of common stock under a Rule 10b5-1 plan on 09/02/2025. The Form 4 shows two reported sale groupings: 508 shares sold at a weighted average price of $87.03 (individual trades ranged $86.50–$87.49) and 2,617 shares sold at a weighted average price of $88.33 (individual trades ranged $87.74–$88.71).

After these transactions the reporting person beneficially owned 11,992 shares held by the John Coghlan Living Trust and 9,375 shares held by the same trust, plus 67,604 shares held by The John Philip Coghlan 2025 Grantor Retained Annuity Trust. The filings note 3,344 restricted stock units that convert to shares upon vesting. The sales were effected pursuant to a 10b5-1 plan adopted December 6, 2024.

Positive

• Sales were executed under a Rule 10b5-1 plan, indicating pre-arranged transactions established when the reporting person stated he lacked material nonpublic information.
• Filing discloses detailed execution ranges and weighted-average prices ($86.50–$87.49 and $87.74–$88.71 ranges; weighted averages $87.03 and $88.33), improving transparency.
• Substantial remaining beneficial ownership disclosed (67,604 shares in the 2025 Grantor Retained Annuity Trust plus holdings in the John Coghlan Living Trust).

Negative

• Director sold shares, which could be perceived negatively by some investors despite being pre-scheduled.
• Form shows multiple indirect holdings and trusts, which can complicate clear assessment of immediate insider economic exposure.

Insights

Financial Analyst

TL;DR: Director stock sales under a pre-arranged 10b5-1 plan; holdings remain material, no new insider signal provided.

The Form 4 documents routine disposition activity rather than opportunistic trading: sales occurred pursuant to a Rule 10b5-1 plan established when the filer stated he lacked material nonpublic information. Quantities sold are modest relative to the total beneficial holdings disclosed (sums of tens of thousands of shares remain across trusts). The weighted-average prices and disclosed ranges provide transparency on execution levels. For investors this is a standard insider liquidity event with no disclosed change in ownership structure or control.

Corporate Governance Expert

TL;DR: Governance-friendly disclosure: sales pre-scheduled under 10b5-1 and signed by attorney-in-fact; documentation appears compliant.

The filing explicitly states the trades were executed under a 10b5-1 plan adopted on December 6, 2024, which supports the affirmative defense against insider trading claims if plan terms were met. The signature by an attorney-in-fact is included and the Form 4 discloses indirect ownership through named trusts and RSUs. There is no indication of departures, new grants outside the trusts, or amendments that would raise immediate governance concerns.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COGHLAN JOHN PHILIP

(Last) (First) (Middle)

C/O LIFE360, INC.

1900 SOUTH NORFOLK STREET, SUITE 310

(Street)

SAN MATEO CA 94403

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Life360, Inc. [ LIF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	09/02/2025		S(1)		508	D	$87.03(2)	11,992	I	Held by the John Coghlan Living Trust
Common stock	09/02/2025		S(1)		2,617	D	$88.33(3)	9,375	I	Held by the John Coghlan Living Trust
Common stock								3,344(4)	D
Common Stock								67,604	I	Held by The John Philip Coghlan 2025 Grantor Retained Annuity Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2024. The Rule 10b5-1 trading plan is a pre-arranged written trading plan pursuant to which shares of Company stock are sold automatically based on a predetermined formula that was established by the Reporting Person at a time when the Reporting Person was not aware of any material nonpublic information about the Company.

2. The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $86.50 to $87.49, inclusive, per share. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full details regarding the number of shares sold at each separate price within the range.

3. The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $87.74 to $88.71, inclusive, per share. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full details regarding the number of shares sold at each separate price within the range.

4. Reflects 3,344 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock upon vesting.

Remarks:

	/s/ Jay Sood, as Attorney-in-Fact	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Life360 (LIF) director John Philip Coghlan sell on 09/02/2025?

He sold 508 shares$87.032,617 shares at a weighted average of $88.33

Were the sales by John Philip Coghlan pre-arranged under a trading plan?

Yes. The Form 4 states the trades were effected pursuant to a Rule 10b5-1 trading plan adopted December 6, 2024.

How many shares does the reporting person still beneficially own according to the Form 4?

The filing reports 11,9929,37567,604

Does the Form 4 disclose any derivative or option transactions?

No. Table II for derivative securities contains no reported transactions in this filing.

What are the 3,344 units mentioned in the filing?

They are restricted stock units (RSUs), each representing a contingent right to receive one share upon vesting, noted as 3,344 RSUs.